Amgen Inc. (AMGN) News Headlines

▮ More

Date

Headline

8/3/2021 4:08:18 PM Amgen Inc. Q2 adjusted earnings of $4.38 per share

8/3/2021 4:03:27 PM Amgen Q2 EPS $0.81 Vs. $3.05 Year Ago

8/3/2021 6:00:19 AM Amgen Q2 21 Earnings Conference Call At 5:00 PM ET

7/30/2021 4:03:56 PM Amgen Declares Quarterly Dividend Of $1.76/share, Payable Sept. 8/ Record Aug. 17

7/30/2021 4:02:36 PM Amgen Inc. (AMGN) Declares $ 1.76 Dividend for Q3 21, Record Date 8/17/2021

7/29/2021 7:41:58 PM Amgen Appoints Omar Ishrak To Board Of Directors

7/27/2021 6:37:21 PM Amgen To Acquire Teneobio For $900 Mln

7/27/2021 4:20:40 PM Amgen To Acquire Privately Held Teneobio For $900 Mln In Cash

7/8/2021 2:26:22 AM Amgen : FDA Grants Priority Review For Tezepelumab In Treatment Of Asthma

7/8/2021 2:04:22 AM Amgen : Tezepelumab Granted Priority Review By FDA

6/23/2021 6:04:56 AM Amgen: Aimovig Approved In Japan To Suppress Onset Of Migraine Attacks In Adults

6/23/2021 4:01:21 AM Amgen Announces Approval Of Aimovig In Japan For Suppression Of Onset Of Migraine Attacks In Adults

6/9/2021 3:01:18 PM Amgen To Present At Goldman Sachs Global Healthcare Conference; Webcast At 4:40 PM ET

6/4/2021 10:21:24 AM Amgen Says Follow-up Phase 2 FIGHT Trial Data Shows Improved OS - Quick Facts

6/3/2021 12:30:13 PM Amgen To Present At The 2021 Jefferies Healthcare Conference; Webcast At 1:30 PM ET

6/1/2021 5:01:31 AM Amgen, Kyowa Kirin To Jointly Develop, Commercialize KHK4083 - Quick Facts

5/17/2021 11:17:56 AM Sandoz Says US Supreme Court Denies Its Petition To Review Biosimilar Erelzi Case

5/13/2021 3:34:56 AM Amgen Says, 'Tezepelumab Reduced Exacerbations Requiring Hospitalization By 85%'

5/13/2021 2:03:07 AM Amgen, AstraZeneca Announce Detailed Results For Tezepelumab From Pivotal NAVIGATOR Phase 3 Trial

5/11/2021 9:29:21 AM Amgen To Present Four Cardiovascular Research Abstracts